OTC:CC - Ocumetics Reports Continued Improvement in First Group of Patients. Early Vision Results Surpass Expectations
(TheNewswire)
Calgary, Alberta – TheNewswire - November 5, 2025 -Ocumetics Technology Corp . (“Ocumetics” or the “Company”)(TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generationophthalmic technology, today announced encouraging o ne-month results from all patients in Group 1 of itsfirst-in-human clinical study evaluating the Ocumetics AccommodatingIntraocular Lens (the “Ocumetics Lens”).
Ocumetics completed Group 1 surgeries in August 2025 (“Day 1”) andcompleted additional Group 1 surgeries in September 2025 (“Day2”). All Group 1 patients (Day 1 and Day 2) have now completed theirone-month postoperative exams, showing Corrected Distance VisualAcuity (CDVA) ranging from 20/32 to 20/25.
“We are thrilled by the visual outcomes we’re seeing in our firstgroup of patients,” said Dean Burns, President and CEO of Ocumetics.“These results have met, and in some cases, exceeded internalexpectations at this early stage of recovery. Every Group 1 patient isshowing steady improvement with visual acuity. These results stronglyreinforce our belief in the transformative potential of the OcumeticsLens.”
Patients in Group 1 began the study with significantly impaireddistance vision due to cataracts. The visual gains seenas early as one month are particularly encouraging.
Dr. Doyle Stulting, Chief Medical Officer of Ocumetics, added,“Achieving 20/32 or better vision this soon after surgery isremarkable. These data highlight the excellent optical quality andstability of the Ocumetics Lens and give us great confidence as weadvance to the next patient groups.”
As a reminder, the primary objectives of Group 1 were to confirmsafety, evaluate surgical technique, and assess distance visionrestoration. The results to date demonstrate that the Ocumetics Lensperforms as designed providing safe implantation and strong opticalperformance.
“We’re seeing early proof of what we set out to achieve; a nextgeneration intraocular lens that gives a patient the vision they oncehad,” added Burns. “Our focus now is on maintaining our momentumas we advance to Group 2 and 3 surgeries.”
Planning for Group 2 surgeries is now underway, with updates to followin the coming weeks.
About Ocumetics
Ocumetics Technology Corp. ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO)is a Canadian research and product development company that is dedicated to developing advanced visioncorrection solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims totransform the field of ophthalmology with state-of-the-art intraocularlenses and other vision-enhancing technologies.
Ocumetics is in the first-in-human early feasibilitystudy phase of a game-changing technology for the ophthalmic industry. Ocumetics has developed an intraocular lens that fits within thenatural lens compartment of the eye, potentially to eliminate the needfor corrective lenses. It is designed to allow the eye’s naturalmuscle activity to shift focus from distance to near, providing clearvision at all distances without the help of glasses or contact lenses.
FOR FURTHER INFORMATION, PLEASECONTACT:
Dave Burwell
Director, Investor Relations
(403) 410-7907
Neither the TSXVenture Exchange nor its Regulation Services Provider (as that term isdefined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKINGINFORMATION: This news release includes certain “forward-lookingstatements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to,statements with respect to the commencement,timing and scope of the research and development to be conducted bythe Corporation mentioned above. Forward-looking statements arenecessarily based upon a number of estimates and assumptions that,while considered reasonable, are subject to known and unknown risks,uncertainties, and other factors which may cause the actual resultsand future events to differ materially from those expressed or impliedby such forward-looking statements. Such factors include but are notlimited to: operational matters, historical trends, current conditionsand expected future developments, access to financing as well as otherconsiderations that are believed to be appropriate in thecircumstances. There can be no assurance that such statements willprove to be accurate, as actual results and future events could differmaterially from those anticipated in such statements. Accordingly,readers should not place undue reliance on forward-looking statements. The Corporation disclaims any intention or obligation to update orrevise any forward-looking statements, whether as a result of newinformation, future events or otherwise, except as required bylaw.
Copyright (c) 2025 TheNewswire - All rights reserved.